Find out, one of the most popular weight loss drugs is not only helping you shed extra pounds, but can also serve you with some other benefits.Recent studies suggest that ozmpic and similar GLP -1 receptor can have anti -cancer effects, potentially some can reduce the risk of some cancer, especially with obesity.These drugs, mainly used for type 2 diabetes and weight loss, have shown the promise in restoring the function of natural killer cells, which are important to fight cancer.Read on to know more.
What does the research say?
Recent research indicates that weight loss injections, known as GLP -1 receptor agonists, can provide significant cancer benefits beyond their role in reducing weight loss. While the evidence connecting weight loss to the low risk of cancer is established, this study suggests that the injections themselves can have more direct effects.Researchers propose that potential anti-cancer effects may be attributed to the ability to reduce inflammation of these drugs. Among various GLP-1 receptor agonists, new yogas are considered the most impact. These drugs suppress appetite, which supports individuals in losing weight. They are available through NHS for high BMI individuals and can also be obtained privately.Nevertheless, experts emphasize that additional research is necessary to widely understand the relationship between weight loss injection and cancer prevention. Notable GLP-1 receptor agonists include semaglutide (vegovi and ozmpic), tirzepetide (maunejaro), liraglutide (sexbanda), and achenatide, of which the latter has been closed.
Overweight or obesity suffering is another major cause of cancer in the UK, which is responsible for one of the 20 cancer cases. Risk increases with high levels of obesity and long periods of excess weight. Maintaining a healthy weight is associated with low risks for 13 different types of cancer, including breasts, bowels, pancreatic, esophagal and gallbladder cancer. StudyPublished in the Econical Meedicin Journal, Malaga was presented in the European Congress on obesity. It was discovered that the first generation GLP -1 receptor agonists, such as liraglutide and accenatide, can provide anti -cancer benefits that expand beyond weight loss. Research indicated the same rates of cancer related to obesity in patients treated with these drugs and patients undergoing bariatric surgery.
Conclusion and insight:
Cum-Leed author Dr. from Clalit Health Services at Tel-Aviv. Yale Wolf Sagi commented on findings, given that GLP -1 receptor agonist “was 41 percent more effective in preventing obesity related cancer.” He emphasized that while the accurate mechanisms of GLP-1s are not yet fully understood, this research connects the growing evidence that weight loss alone does not include all metabolism and anti-cancer benefits of these drugs.In this study, researchers analyzed people with electronic health records and type 2 diabetes of coarse, all of the history of cancer, which were treated with the first generation GLP -1 receptor agonist. In the average follow -up period of 7.5 years, 298 patients were diagnosed with obesity related cancer, with the most prevalent breast, bowel, and pregnancy cancer.The analysis found that 150 out of 3,178 patients who undergoed bariatric surgery developed obesity -related cancer, while 148 out of 3,178 patients took GLP -1 receptor agonists, which highlighted the relative effectiveness of biatric surgery to reduce the risk of cancer. However, further investigation suggested that GLP -1 drugs had a direct impact in reducing cancer related to obesity, showing 41 percent less relative risk than biatric surgery.
Professor Dicker, co -author of Hasharon Hospital, Rabin Medical Center in Israel, commented on the versatile protective effects of the GLP -1 receptor agonist against obesity related cancer, which included him responsible for various mechanisms, including a decrease in inflammation. He said that the long -term follow -up of the study allowed for a unique comparison of the effects between GLP -1 receptor agonists and surgical intervention, especially considering the long delay periods associated with cancer.The new generation GLP-1 receptor agonists, which display more efficacy in weight loss, can provide additional benefits in reducing the risk of obesity related to obesity; However, further research has been warned to ensure that these drugs do not inadvertently increase the risk for non-motor-related cancer.Neveda Sattar, a professor at cardiometabolic medicine at the University of Glasgow, emphasized the requirement of large tests with carefully matched colleagues to examine these principles. He warned that while the findings of this study are complicated, they do not provide definite evidence about the relationship between the groups, due to their observation design and significant basic differences, an integrin-based treatments and the risk of cancer.Sattar advocated large result tests vs. Placebo controls to gain a clear understanding of the link between these drugs and cancer risk, suggesting that several such studies could give results in the next five years.
Here is a more wide form:
Low risk of obesity related cancer: Studies have shown that GLP -1 receptor agonists, such as ozmpic and vegovi, colorectal, esophagals, endometrial, gallbladles, kidney, liver, liver, ovarian, and pancreatic cancer, including some obesity related to obesity, can reduce the risk of developing cancer related to obesity.
Possible mechanism: An important discovery is that these drugs can restore the function of natural killer cells, which are weak in obese individuals. Natural killer cells play an important role in fighting cancer by identifying and destroying cancer cells. Experts believe that semaglutide, an active ingredient in ozapic and vegovi, can improve the function of these cells, potentially reduce the risk of cancer.Beyond weight loss: Anti-cancer effects of GLP-1 drugs are not attributed only to weight loss. Researchers believe that these drugs can reduce inflammation and help the immune system destroy cancer cells before making tumors. This suggests that GLP-1 drugs can play a broader role in cancer prevention and potentially treatment. More research needs: While conclusions are promising, more research is required to fully understand the potential anti -cancer benefits of GLP -1 drugs. Studies are running to detect mechanisms by which these drugs can reduce the risk of cancer and determine the best ways to use them in cancer prevention and treatment.
